What is Indaptus Therapeutics Earnings Power Value (EPV)?
As of Mar24, Indaptus Therapeutics's earnings power value is $1.14. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Indaptus Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Indaptus Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics Earnings Power Value (EPV) Chart
|
Indaptus Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Indaptus Therapeutics Quarterly Data
|
|
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Indaptus Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Indaptus Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Earnings Power Value (EPV) falls into.
Indaptus Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
| Glen R. Anderson |
10 percent owner |
3274 ROSS ROAD, PALO ALTO CA 94303 |
| Roger J. Waltzman |
officer: Chief Medical Officer |
C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
| Robert Martell |
director |
4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Boyan Vesselinov Litchev |
officer: Chief Medical Officer |
13357 RUSSET LEAF LN., SAN DIEGO CA 92129 |
| Jeffrey A Meckler |
director, officer: Chief Executive Officer |
740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
| Walt Addison Linscott |
officer: Chief Business Officer |
1860 MONTREAL ROAD, TUCKER GA 30084 |
| Michael James Newman |
director, 10 percent owner, officer: Chief Scientific Officer |
C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
| Mark John Gilbert |
director |
13731 NORTHWOOD RD., NW, SEATTLE WA 98177 |
| Brian O'callaghan |
director |
550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
| Hoonmo Lee |
director, 10 percent owner |
C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
| Anthony J Maddaluna |
director |
PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017 |
| William B Hayes |
director |
231 MAPLE AVENUE, BURLINGTON NC 27215 |
| Roger Pomerantz |
director |
711 HARVEST HILL ROAD, CHALFONT PA 18914 |
| Hila Karah |
director |
9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900 |
| Nir Sassi |
officer: Chief Financial Officer |
3 ELUL STREET, APT. 6, MODIIN L3 7176397 |
Indaptus Therapeutics (Indaptus Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your